Leptomeningeal collateral vessels help redistribute cerebral blood flow following arterial obstruction, reducing tissue damage. This study investigates the Tie2 receptor peptide agonist Vasculotide in a permanent middle cerebral artery occlusion (pMCAO) model. Vasculotide enhanced early diameter enlargement of pre-existing pial collaterals, which may be mediated by structural remodeling, as evidenced by endothelial proliferation. These changes correlated with reduced infarct volume, blood-brain barrier disruption, enhanced blood flow, and functional recovery at 3-28 days post-pMCAO. Conditional endothelial cell (EC)-specific EphA4 knockout (KO) mice exhibited increased Tie2 and Ang-1 expression, mimicking the effects of Vasculotide on collateral size. Simultaneous genetic loss of EC-specific EphA4 and Tie2 attenuated these outcomes. Nitric oxide inhibition partially blocked collateral enlargement in EC-KO mice, suggesting the presence of additional contributors. Bulk RNAseq of meningeal tissue revealed upregulation of Krt5, Krt14, and Col17a1 in the ipsilateral meninges of Vasculotide-treated and EC-specific EphA4 KO mice. Notably, the number of Krt5-expressing cells is increased on the leptomeningeal arterial vasculature of KO mice, suggesting a novel contribution to collateral enlargement. The opposing roles of EphA4 and Tie2 in collateral dynamics are demonstrated, and a novel molecular program is identified that can be targeted to enhance their diameter enlargement in ischemic stroke.
Tie2-Dependent Mechanisms Influence Leptomeningeal Collateral Dynamics and Reperfusion Following Stroke.
阅读:3
作者:Kaloss Alexandra M, de Jager Caroline, Lyles Kennedie, Groot Nathalie A, Zhu Jackie, Lin Yu, Chen Michael, Xie Hehuang, Matson John B, Theus Michelle H
| 期刊: | Advanced Science | 影响因子: | 14.100 |
| 时间: | 2026 | 起止号: | 2026 Jan;13(3):e05342 |
| doi: | 10.1002/advs.202505342 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
